Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²)
Men who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial
Participants with Normal Renal Function:
Have estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) greater than or equal to 90 milliliter per minute (mL/min)
Participants with Renal Impairment:
Severe renal impairment: Have eGFR determined by CKD-EPI of less than 30 mL/min and not requiring dialysis
ESRD: Participants who have been on a stable hemodialysis schedule for at least 3 months prior to planned dosing
You may not be if
Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition
Have any abnormality in the 12-lead electrocardiogram (ECG)
Hemoglobin less than 8 grams per deciliter (g/dL) and clinically significant anemia symptoms
Have known allergies to LY3819469, related compounds or any components of the formulation, or a history of significant atopy
Have participated in any Lp(a) siRNA therapeutic clinical trial within the last 1 year
Clareo Health | A Study of LY3819469 in Participants With Impaired and Normal Renal Function
